A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) (LAM)

Clinical Trial ID NCT03062943

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.	Cell	2005	7.75